GW 7647 at 10 μM significantly increased PPARα mRNA levels in Huh-7 cells. In WT mouse hepatocytes treated for 24 h, the lowest benchmark concentrations for PPARα target genes were approximately 0.013 µM. In primary hepatocytes, treatment at 10 µM for 24 h decreased Lgr5 expression; downregulation observed with different doses in WT mouse hepatocytes was abolished in PPARα KO mouse cells. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
PPARα mRNA Expression in Huh-7 Cells
Cell-based study · Huh-7 cells [1]
Huh-7 cells were treated at 10 μM, with BSA as the control. Treatment significantly increased PPARα mRNA levels, assessed by real-time RT-PCR.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 24-hour-treated
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: GW 7647
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > PPARα activation reverses palmitic acid-induced lipotoxicity (S151); Fig. 4 legend (S223)
Real-time RT-PCR analysis of PPARα: Real-time RT-PCR analysis of PPARα; comparator: BSA — Results > PPARα activation reverses palmitic acid-induced lipotoxicity (S151); Fig. 4 legend (S223)
Benchmark concentrations in WT mouse hepatocytes
Cell-based study · WT mouse hepatocytes [2]
WT mouse hepatocytes were treated with GW 7647 for 24 h. The lowest benchmark concentrations for PPARα target genes were approximately 0.013 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01, 0.1, 1, or 10 μM
- Exposure duration
- 24 h
- Method
- supplemented modified Eagle’s medium
- Vehicle
- dimethylsulfoxide (0.1%; cell culture grade; Sigma Aldrich)
Methods and source locations
Compound reported in the paper: GW 7647
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Untitled > Untitled > Hepatocyte treatments (S16, S17, S18); Materials and methods > Untitled > Untitled > Differential gene expression analyses (S35); Results > Untitled > Benchmark concentration modeling of gene expression data from WT and PPARα KO mouse hepatocytes (S133)
lowest BMCs for PPARα target genes: lowest BMCs for PPARα target genes; comparator: solvent control — Results > Untitled > Benchmark concentration modeling of gene expression data from WT and PPARα KO mouse hepatocytes (S133)
Lgr5 expression in primary hepatocytes
Cell-based study · primary hepatocytes; n = 3 per group [3]
QRT-PCR analysis of Lgr5 expression in primary hepatocytes treated with GW7647 (10 µM) or DMSO for 24 h: decreasing Lgr5 expression. Additionally, different doses of GW7647 induces down-regulation of Lgr5 expression in hepatocytes from WT mice and was abolished in PPARα KO mouse cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- 24 h
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: GW 7647
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > PPARα activation suppresses Lgr5 expression (S79, S80); Figure 2 legend (S141)
QRT-PCR analysis of PPARα, Cpt1a and Lgr5 expression: QRT-PCR analysis of PPARα, Cpt1a and Lgr5 expression; comparator: DMSO — Results > PPARα activation suppresses Lgr5 expression (S79, S80); Figure 2 legend (S141)